{"id":"nct:NCT07866066","kind":"trial","title":"Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes","authors":["Amgen"],"author_count":1,"year":2026,"published":"2026-10-08","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07866066","source_url":"https://clinicaltrials.gov/study/NCT07866066","archive_url":"https://space-kitty.com/papers/nct:NCT07866066","updated":"2026-10-08","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Diabetes Mellitus, Type 2"],"details":{"acronym":"MARITIME-T2D-3","status":"NOT_YET_RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1300,"sponsor":"Amgen","conditions":["Diabetes Mellitus, Type 2"],"interventions":["DRUG: Maridebart cafraglutide","DRUG: Semaglutide"],"start_date":"2026-11-02","start_date_type":"ESTIMATED","primary_completion_date":"2028-09-04","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}